Immunotherapy can help some people with ovarian cancer, but it is not a routine treatment for every stage or every tumour. The strongest current use is in carefully selected situations defined by the cancer’s treatment history and biomarkers. In February 2026, the US FDA approved pembrolizumab with weekly paclitaxel, with or without bevacizumab, for certain previously treated, platinum-resistant ovarian cancers that test PD-L1 positive. Other first-line immunotherapy combinations remain emerging evidence rather than a universal standard.
This guide explains when immunotherapy may be considered, which tests matter, what recent trials actually found and why the words “new treatment” do not automatically mean “better treatment” for an individual patient.
In plain words: for most women with ovarian cancer, immunotherapy has limited proven benefit and is not the main treatment. Surgery, chemotherapy and, for some, maintenance tablets remain the core of treatment. Families sometimes search for this in Hindi as “immunotherapy kya hai” or अंडाशय के कैंसर में इम्यूनोथेरेपी (andashay ke cancer mein immunotherapy).
On This Page
Does Immunotherapy Work for Ovarian Cancer?
Yes, but only in selected situations. Ovarian cancer has generally responded less consistently to immune-checkpoint medicines than cancers such as melanoma, lung cancer or some endometrial cancers. A patient’s chance of benefit depends on the cancer subtype, whether it is newly diagnosed or recurrent, platinum sensitivity, previous treatment, PD-L1 and other biomarkers, and the exact treatment combination.
One important current example is pembrolizumab combined with paclitaxel, with or without bevacizumab, for previously treated platinum-resistant disease whose tumour is PD-L1 positive. In the KEYNOTE-B96 trial, adding pembrolizumab in this group delayed cancer growth and also helped patients live longer on average. Results from first-line trials combining immunotherapy with PARP inhibitors are more mixed: some delayed progression, but they have not yet shown that every patient lives longer.
Immunotherapy should therefore be discussed as a specific treatment option with defined eligibility, not as a general replacement for surgery, chemotherapy or biomarker-directed maintenance.
What Is Immunotherapy for Ovarian Cancer?
Immunotherapy helps the immune system recognise or attack cancer. The medicines discussed most often in ovarian cancer are immune-checkpoint inhibitors. These block signals such as PD-1 or PD-L1 that can restrain immune cells.
Examples include:
- Pembrolizumab (Keytruda), which blocks PD-1;
- Dostarlimab (Jemperli), another PD-1 inhibitor; and
- Durvalumab (Imfinzi), which blocks PD-L1.
These names do not describe interchangeable treatments. Evidence and approval depend on the cancer setting, accompanying medicines, biomarkers and country. A medicine approved for endometrial cancer is not automatically approved for ovarian cancer.
When May Immunotherapy Be Used for Ovarian Cancer?
The clearest recently established setting is a specific group with recurrent disease. In February 2026, the US FDA approved pembrolizumab with weekly paclitaxel, with or without bevacizumab, for adults with epithelial ovarian, fallopian-tube or primary peritoneal cancer when all of the following applied:
- the cancer was platinum resistant, meaning it progressed within six months after the last platinum chemotherapy;
- the tumour expressed PD-L1 with a combined positive score (CPS) of at least 1 using an authorised test; and
- the patient had received one or two previous systemic treatment regimens.
This approval was based on the KEYNOTE-B96 trial. It should not be expanded to every person with recurrent ovarian cancer, every PD-L1 result or every chemotherapy schedule.
Immunotherapy may also be discussed when a tumour has a rare biomarker that supports a tumour-agnostic indication, or through an appropriate clinical trial. The exact regulatory indication and availability must be checked in the country where treatment will be given.
Which Tests Help Decide Whether Immunotherapy Is Suitable?
No single test predicts benefit perfectly. Depending on the clinical situation, relevant information can include:
- PD-L1 testing: reports expression using a scoring system such as CPS. The required assay and cutoff depend on the treatment indication.
- Mismatch-repair or microsatellite-instability testing: dMMR or MSI-high cancers may be more sensitive to checkpoint inhibition, although these findings are uncommon in the most frequent high-grade serous ovarian cancers.
- Tumour mutational burden: a high result can be relevant to some tumour-agnostic immunotherapy pathways.
- BRCA and HRD testing: these primarily help guide PARP-inhibitor decisions. They are not the same as PD-L1 testing, although combination trials may use several biomarker groups.
- Pathology subtype: high-grade serous, clear-cell, endometrioid, low-grade serous and mucinous cancers do not share identical biology or evidence.
Ask for the complete pathology and molecular reports. “The genetic test was negative” does not explain whether germline BRCA, tumour BRCA, HRD, PD-L1, MMR or another marker was tested.
Is Immunotherapy Used for Stage 3 or Stage 4 Ovarian Cancer?
Stage alone does not decide whether immunotherapy should be used. Most newly diagnosed Stage 3 and Stage 4 epithelial ovarian cancers are treated with a combination of cytoreductive surgery and platinum-based chemotherapy, sometimes with bevacizumab and later PARP-inhibitor maintenance depending on response and biomarkers.
For a newly diagnosed patient, first-line immunotherapy combinations such as those studied in FIRST and DUO-O require careful interpretation. A positive trial result does not automatically displace established first-line treatment.
For recurrent disease, the platinum-free interval, number of previous treatments, pathology, PD-L1 result, symptoms and fitness for chemotherapy can matter more than the original stage number.
What Did the FIRST Trial Show About Dostarlimab and Niraparib?
The phase 3 FIRST/ENGOT-OV44 trial studied newly diagnosed Stage 3 or Stage 4 non-mucinous epithelial ovarian cancer. It compared:
- platinum-based chemotherapy followed by niraparib maintenance; with
- the same general strategy plus dostarlimab during chemotherapy and dostarlimab with niraparib during maintenance.
Bevacizumab could be used in either group when selected by the investigator. Among the 1,138 patients in the main comparison, median progression-free survival was 20.6 months with dostarlimab versus 19.2 months without it. The hazard ratio was 0.85.
The difference was statistically significant, but the investigators described it as clinically modest. Median overall survival was 44.4 months with dostarlimab and 45.4 months without it; there was no statistically significant overall-survival improvement.
This means the trial does not support saying that dostarlimab plus niraparib helps every patient live longer. It provides evidence of a small average delay in progression from adding immunotherapy to an active treatment plan.
What Did the DUO-O Trial Show?
DUO-O tested a different first-line combination: durvalumab with chemotherapy and bevacizumab, followed by durvalumab, bevacizumab and olaparib maintenance in patients without a tumour BRCA mutation.
The full combination improved progression-free survival, with a larger numerical effect in the HRD-positive group. Durvalumab without olaparib did not show the same benefit, and an overall-survival advantage has not yet been demonstrated.
Because the medicines, patient population and trial design differed, FIRST and DUO-O should not be treated as copies of the same result. Read the detailed DUO-O patient guide for the exact numbers and limitations.
Why Does Immunotherapy Not Help Everyone With Ovarian Cancer?
Many ovarian cancers have an immune environment that makes it difficult for activated immune cells to enter or remain effective inside the tumour. Ovarian cancer is also not one disease: its subtypes have different mutations, immune features and treatment sensitivities.
Earlier checkpoint-inhibitor trials in unselected ovarian-cancer populations often found low response rates or failed to improve survival. More recent research therefore focuses on:
- selecting patients through biomarkers such as PD-L1;
- combining immunotherapy with chemotherapy, anti-angiogenic treatment or PARP inhibitors;
- understanding which cancer subtypes are more immune responsive; and
- developing vaccines, cellular therapies and other immune approaches within trials.
A combination can also add toxicity and cost. A small average delay in progression may or may not justify that burden for an individual patient.
What Side Effects Can Ovarian-Cancer Immunotherapy Cause?
Checkpoint inhibitors can cause fatigue, rash, itching, diarrhoea, appetite changes and infusion reactions. More serious effects occur when the activated immune system inflames healthy organs.
Immune-related problems can affect:
- the lungs, causing new cough or breathlessness;
- the bowel, causing persistent diarrhoea or abdominal pain;
- the liver, causing abnormal blood tests or jaundice;
- the thyroid, pituitary or adrenal glands, causing marked fatigue, headache, dizziness or hormonal changes;
- the kidneys, skin, nervous system, heart or other organs.
Some reactions occur during treatment and others appear after a dose has been delayed or stopped. Report new symptoms early. Steroids or other immune-suppressing treatment may be required, and immunotherapy may need to be paused.
When immunotherapy is combined with paclitaxel, bevacizumab, niraparib or olaparib, patients can also experience the known side effects of those medicines. Monitoring must cover the whole combination.
Is Immunotherapy for Ovarian Cancer Available in India?
Several immunotherapy medicines are available in India, but availability of a medicine does not prove that every cancer indication or combination is approved. For example, GSK’s published Indian information describes dostarlimab for certain advanced dMMR/MSI-high endometrial cancers and niraparib as first-line ovarian-cancer maintenance. It does not describe the FIRST dostarlimab–niraparib ovarian-cancer combination as an approved Indian indication.
The February 2026 pembrolizumab ovarian-cancer approval was issued by the US FDA. Patients in India should ask the treating medical oncologist to verify:
- the current Indian indication for the exact drug and combination;
- whether the required PD-L1 or other test was performed with an appropriate assay;
- whether treatment would be approved, off label or available only through a trial;
- expected benefit compared with established alternatives; and
- cost, insurance approval, infusion schedule and monitoring.
Questions to Ask Your Ovarian-Cancer Specialist
- Is my cancer newly diagnosed, platinum sensitive or platinum resistant?
- What is the exact histological subtype?
- Has the tumour been tested for PD-L1, MMR/MSI, BRCA and HRD?
- Which result would make immunotherapy reasonable in my case?
- Is the proposed treatment approved for this exact situation in India?
- What improvement was shown in patients like me: response, progression-free survival or overall survival?
- What are the established alternatives?
- Could an autoimmune condition or previous transplant make immunotherapy unsafe?
- Which symptoms require an urgent call during treatment?
- Is there a suitable clinical trial or value in a second opinion?
Frequently Asked Questions
Is immunotherapy a cure for ovarian cancer?
No. Some selected patients benefit, but immunotherapy is not a proven universal cure for ovarian cancer.
Is Keytruda used for ovarian cancer?
Pembrolizumab, also called Keytruda, has a US FDA-approved use with paclitaxel, with or without bevacizumab, for certain previously treated platinum-resistant and PD-L1-positive epithelial ovarian, fallopian-tube or primary peritoneal cancers. Approval and availability in India must be checked separately.
Does immunotherapy work for Stage 4 ovarian cancer?
It can be relevant to selected Stage 4 patients, but stage alone is insufficient. Treatment timing, platinum sensitivity, pathology, biomarkers, previous therapy and medical fitness determine suitability.
Is dostarlimab approved for ovarian cancer?
The FIRST trial studied dostarlimab in newly diagnosed advanced ovarian cancer, but a positive trial result is not the same as regulatory approval. Current Indian information describes dostarlimab’s approved use in certain advanced endometrial cancers, not the FIRST ovarian-cancer combination.
Is niraparib immunotherapy?
No. Niraparib is a PARP inhibitor used as maintenance treatment in ovarian cancer. FIRST tested it together with the immunotherapy drug dostarlimab.
Is mirvetuximab (Elahere) immunotherapy?
No. Mirvetuximab soravtansine is an antibody-drug conjugate: an antibody that carries a chemotherapy drug to cancer cells that have a marker called folate receptor alpha (FRα). It has been studied for FRα-positive platinum-resistant ovarian cancer and needs a specific test. Approval, availability and cost in India must be checked with the treating oncologist.
What is the difference between targeted therapy and immunotherapy?
Targeted medicines act on a particular cancer pathway or vulnerability. Immunotherapy changes immune signals so immune cells can respond to cancer. Some treatment plans combine both approaches.
Does PD-L1 positive mean immunotherapy will definitely work?
No. PD-L1 can identify eligibility for a specific treatment, but it cannot guarantee response. The cancer setting and approved companion treatment also matter.
Should I request immunotherapy instead of chemotherapy?
Usually this is not an either-or decision. The established ovarian-cancer immunotherapy strategies use combinations or apply in selected later-treatment settings. Do not replace prescribed chemotherapy based on an online article.
Related Guidance and Medical Sources
Read the general guide to immunotherapy for gynaecological cancers, the ovarian-cancer treatment pathway, the guide to PARP-inhibitor maintenance, the detailed DUO-O trial explanation, or request a gynaecological-oncology second opinion.